BACKGROUND: : In previous studies we and others have demonstrated an association with apolipoprotein (APOE) ε4 genotype and the presence of cognitive deficits in multiple sclerosis (MS). In this follow-up study, we have assessed whether APOE ε4 status exacerbates progression of cognitive deficits in MS. METHODS: : A total of 197 patients with MS were assessed for APOE genotype, and baseline cognitive performance was measured using a standardized battery of tests. One hundred seventy patients (86.3%) were clinically followed up for 1 year and were assessed for progression of cognitive deficits. RESULTS: : The APOE ε4 allele was present in 24.7% of patients. During 1-year follow-up, significant progression of cognitive deficits was found in APOE ε4 carriers (P=0.001) after logistic regression analysis controlling for sex, ethnicity, age, education, disease duration, severity, and subtype. CONCLUSIONS: : APOE ε4 carriers with MS have worsening progression of cognitive deficits than noncarriers. APOE ε4 carrier status predicts cognitive decline in verbal learning and memory.
BACKGROUND: : In previous studies we and others have demonstrated an association with apolipoprotein (APOE) ε4 genotype and the presence of cognitive deficits in multiple sclerosis (MS). In this follow-up study, we have assessed whether APOE ε4 status exacerbates progression of cognitive deficits in MS. METHODS: : A total of 197 patients with MS were assessed for APOE genotype, and baseline cognitive performance was measured using a standardized battery of tests. One hundred seventy patients (86.3%) were clinically followed up for 1 year and were assessed for progression of cognitive deficits. RESULTS: : The APOE ε4 allele was present in 24.7% of patients. During 1-year follow-up, significant progression of cognitive deficits was found in APOE ε4 carriers (P=0.001) after logistic regression analysis controlling for sex, ethnicity, age, education, disease duration, severity, and subtype. CONCLUSIONS: : APOE ε4 carriers with MS have worsening progression of cognitive deficits than noncarriers. APOE ε4 carrier status predicts cognitive decline in verbal learning and memory.
Authors: Soomin Shin; Katharine A Walz; Angela S Archambault; Julia Sim; Bryan P Bollman; Jessica Koenigsknecht-Talboo; Anne H Cross; David M Holtzman; Gregory F Wu Journal: J Neuroimmunol Date: 2014-03-29 Impact factor: 3.478
Authors: Stephen D Skaper; Massimo Barbierato; Laura Facci; Mila Borri; Gabriella Contarini; Morena Zusso; Pietro Giusti Journal: Mol Neurobiol Date: 2018-01 Impact factor: 5.590
Authors: Leon M Tai; Riya Thomas; Felecia M Marottoli; Kevin P Koster; Takahisa Kanekiyo; Alan W J Morris; Guojun Bu Journal: Acta Neuropathol Date: 2016-02-16 Impact factor: 17.088
Authors: Ruth Elliott; Fan Li; Isabelle Dragomir; Ming Ming W Chua; Brian D Gregory; Susan R Weiss Journal: PLoS One Date: 2013-09-18 Impact factor: 3.240
Authors: Sinah Engel; Christiane Graetz; Anke Salmen; Muthuraman Muthuraman; Gerrit Toenges; Björn Ambrosius; Antonios Bayas; Achim Berthele; Christoph Heesen; Luisa Klotz; Tania Kümpfel; Ralf A Linker; Sven G Meuth; Friedemann Paul; Martin Stangel; Björn Tackenberg; Florian Then Bergh; Hayrettin Tumani; Frank Weber; Brigitte Wildemann; Uwe K Zettl; Gisela Antony; Stefan Bittner; Sergiu Groppa; Bernhard Hemmer; Heinz Wiendl; Ralf Gold; Frauke Zipp; Christina M Lill; Felix Luessi Journal: Neurol Neuroimmunol Neuroinflamm Date: 2020-05-01